Adalimumab for the Treatment of Refractory Acne Conglobata

Freja Lærke Sand, Simon Francis Thomsen

JAMA Dermatology · 2013 · 45 citations · 6 references

Concepts

Abstract

Tumor necrosis factor (TNF) inhibitors have become important components of the treatment of multiple chronic inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn disease, and ulcerative colitis. Furthermore, off-label use of TNF inhibitors has been reported for a variety of other diseases. We report a case of refractory acne conglobata treated with the TNF inhibitor adalimumab.

References

6